PE20221170A1 - Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos - Google Patents

Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos

Info

Publication number
PE20221170A1
PE20221170A1 PE2022000692A PE2022000692A PE20221170A1 PE 20221170 A1 PE20221170 A1 PE 20221170A1 PE 2022000692 A PE2022000692 A PE 2022000692A PE 2022000692 A PE2022000692 A PE 2022000692A PE 20221170 A1 PE20221170 A1 PE 20221170A1
Authority
PE
Peru
Prior art keywords
high purity
cangrelor
pharmaceutical formulations
preparation
methods
Prior art date
Application number
PE2022000692A
Other languages
English (en)
Inventor
Panna Dutta
Far Adel Rafai
Min Ding
Rajeshwar Motheram
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55537309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20221170(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PE20221170A1 publication Critical patent/PE20221170A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta referido al compuesto: acido ([dicloro-[[[(2R,3S,4R,5R)-3,4- dihidroxi-5-[6-(2-metilsulfaniletilamino)-2-(3,3,3- trifluoropropilsulfanil)purin-9-il]oxolan-2-il]metoxihidroxifosforil]oxi- hidroxifosforil]metil]fosfonico (cangrelor). Tambien se refiere a formulaciones farmaceuticas que comprenden, como el ingrediente activo, cangrelor con una alta pureza, donde niveles bajos de impurezas son logrados y mantenidos constantemente. La invencion se refiere tambien a un metodo de inhibicion de activacion, agregacion plaquetaria o ambas, que comprende contactar plaquetas con una cantidad efectiva de un cangrelor de alta pureza, o una sal del mismo, inhibiendo asi la activacion, agregacion plaquetaria o ambas.
PE2022000692A 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos PE20221170A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103136P 2015-01-14 2015-01-14
PCT/US2015/039975 WO2016114818A1 (en) 2015-01-14 2015-07-10 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Publications (1)

Publication Number Publication Date
PE20221170A1 true PE20221170A1 (es) 2022-07-25

Family

ID=55537309

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022000692A PE20221170A1 (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
PE2017001208A PE20171246A1 (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017001208A PE20171246A1 (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos

Country Status (13)

Country Link
US (4) US9295687B1 (es)
EP (1) EP3244900A4 (es)
KR (1) KR102440847B1 (es)
CN (2) CN107206014A (es)
BR (1) BR112017014996A2 (es)
CA (1) CA2971868C (es)
CL (1) CL2017001840A1 (es)
CO (1) CO2017006958A2 (es)
MA (1) MA41326A (es)
MX (1) MX2017009289A (es)
PE (2) PE20221170A1 (es)
RU (1) RU2733409C2 (es)
WO (1) WO2016114818A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582480B (zh) * 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
BR112017014996A2 (pt) * 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法
CN109781920B (zh) * 2017-11-15 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种坎格雷洛有关物质的hplc检测方法
CN109912674A (zh) 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406649T2 (de) 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
GB9813646D0 (en) * 1998-06-24 1998-08-26 Ciba Geigy Ag Organic compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
WO2003026642A1 (fr) 2001-09-21 2003-04-03 Sumitomo Pharmaceuticals Co., Ltd. Preparation pharmaceutique lyophilisee
DE60321450D1 (de) 2002-02-22 2008-07-17 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9925265B2 (en) * 2009-11-11 2018-03-27 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2011041217A1 (en) * 2009-10-02 2011-04-07 Schering Corporation The use of a par-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103582480B (zh) * 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
BR112014016764A8 (pt) * 2012-01-04 2017-07-04 The Medicines Co métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor
CN103860459A (zh) * 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
BR112017014996A2 (pt) * 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados

Also Published As

Publication number Publication date
MX2017009289A (es) 2017-10-11
US20160199400A1 (en) 2016-07-14
US20160296549A1 (en) 2016-10-13
US20170304345A1 (en) 2017-10-26
US9295687B1 (en) 2016-03-29
EP3244900A1 (en) 2017-11-22
CO2017006958A2 (es) 2017-11-30
KR102440847B1 (ko) 2022-09-06
MA41326A (fr) 2021-04-28
CN115990138A (zh) 2023-04-21
US9700575B2 (en) 2017-07-11
RU2733409C2 (ru) 2020-10-01
CL2017001840A1 (es) 2017-12-29
KR20170103848A (ko) 2017-09-13
WO2016114818A1 (en) 2016-07-21
EP3244900A4 (en) 2018-05-30
CA2971868C (en) 2023-04-04
US10039780B2 (en) 2018-08-07
US9439921B2 (en) 2016-09-13
CA2971868A1 (en) 2016-07-21
RU2017127531A3 (es) 2019-02-14
PE20171246A1 (es) 2017-08-24
BR112017014996A2 (pt) 2018-03-20
CN107206014A (zh) 2017-09-26
RU2017127531A (ru) 2019-02-14

Similar Documents

Publication Publication Date Title
PE20221170A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
BR112018008880A2 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
DOP2016000124A (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
CL2018001356A1 (es) Inhibidores de pirazol de acc y usos de los mismos.
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CR20130663A (es) Composiciones farmcéuticas inhalables
BR112016002233A2 (pt) composições de adoçante
UY35940A (es) Nuevas pirazolil-heteroarilamidas como agentes plaguicidas
CU20160072A7 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
DOP2016000253A (es) Nuevos compuestos
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
BR112015022587A2 (pt) formulações de citocina quimérica para entrega ocular
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112017005821A2 (pt) formulação aquosa, método para a preparação de uma formulação aquosa, conjunto, método para a preparação de uma composição farmacêutica, composição farmacêutica e método para quimicamente estabilizar uma formulação aquosa
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.